Verified Nov 2026
Other
·

Washington, District of Columbia
·
Since 2003
Vanda Pharmaceuticals is a biopharmaceutical company headquartered in Washington, D.C., founded in 2003, with 500–1,000 employees and estimated annual revenue of $100–250 million. The company develops and commercializes therapies for central nervous system disorders and rare diseases. Its approved portfolio includes HETLIOZ for sleep-wake disorders, Fanapt for bipolar disorder and schizophrenia, PONVORY for multiple sclerosis, and NEREUS for motion-induced vomiting.
Vanda Pharmaceuticals at a glance
Revenue
$100-250M
Est. band
Employees
500-1,000
Founded
2003
Headquarters
Washington, District of Columbia
Industries
Automotive
Electric Vehicles
Medical
Overview
Vanda Pharmaceuticals is a biopharmaceutical company headquartered in Washington, D.C., founded in 2003, with 500–1,000 employees and estimated annual revenue of $100–250 million. The company develops and commercializes therapies for central nervous system disorders and rare diseases. Its approved portfolio includes HETLIOZ for sleep-wake disorders, Fanapt for bipolar disorder and schizophrenia, PONVORY for multiple sclerosis, and NEREUS for motion-induced vomiting.
At a glance
Attribute | Detail |
|---|---|
Founded | 2003 |
Headquarters | Washington, District of Columbia |
Employees | 500-1,000 |
Revenue | $100-250M (estimated) |
What Vanda Pharmaceuticals makes
The company advances clinical-stage candidates including Tradipitant for COVID-19 pneumonia and Bysanti for mood disorders, supported by research in genetics and drug discovery.
Latest developments
2026-11-11 — Vanda Pharmaceuticals at Stifel 2026 Healthcare Conference: growth before loe By Investing.com (investing.com)
2026-10-29 — Vanda (VNDA) Q3 2026 Earnings Call Transcript (yahoo.com)
2026-09-15 — Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens By Investing.com (investing.com)
2026-08-05 — Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results (prnewswire.com)
2026-06-22 — GW Athletics Names Vanda Pharmaceuticals First Official Jersey Patch Partner - George Washington University Athletics (gwsports.com)
2026-05-06 — Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results (prnewswire.com)
Company details
Vanda serves patients globally and maintains a focus on improving outcomes in unmet medical needs within neurology and rare disease treatment. Vanda Pharmaceuticals was founded in 2003, has an estimated 500-1,000 employees, and is headquartered in Washington, District of Columbia.
Frequently asked questions
What does Vanda Pharmaceuticals do?
Vanda Pharmaceuticals is a biopharmaceutical company headquartered in Washington, D.C., founded in 2003, with 500–1,000 employees and estimated annual revenue of $100–250 million. The company develops and commercializes therapies for central nervous system disorders and rare diseases. Its approved portfolio includes HETLIOZ for sleep-wake disorders, Fanapt for bipolar disorder and schizophrenia, PONVORY for multiple sclerosis, and NEREUS for motion-induced vomiting.
Where is Vanda Pharmaceuticals headquartered?
Vanda Pharmaceuticals is headquartered in Washington, District of Columbia (2200 Pennsylvania Avenue Northwest, Washington, District of Columbia, 20037).
When was Vanda Pharmaceuticals founded?
Vanda Pharmaceuticals was founded in 2003.
How big is Vanda Pharmaceuticals?
Vanda Pharmaceuticals has an estimated 500-1,000 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
